Acucela Signs Agreement to Develop a Compact OCT for NASA’s Deep Space Missions
SEATTLE--(BUSINESS WIRE)--Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company signed the agreement with the Translational Research Institute for Space Health (TRISH) to develop a compact OCT*1 device for NASA’s Deep Space missions. Approximately 63% of long-duration spaceflight crewmembers present with one or more signs of Spaceflight Associated Neuro-ocular Syndro